Skip to main content
padlock icon - secure page this page is secure

Free Content Alemtuzumab Induction and Prednisone-Free Maintenance Immunotherapy in Simultaneous Pancreas-Kidney Transplantation Comparison With Rabbit Antithymocyte Globulin Induction – Long-Term Results

Download Article:

You have access to the full text article on a website external to Ingenta Connect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

This study compared the effects of using two T-cell depleting antibodies, alemtuzumab (anti-CD 52, Campath-1H®) and rabbit antithymocyte globulin (Thymoglobulin®), as induction immunosuppression for recipients of simultaneous pancreas-kidney transplantation given a prednisone-free maintenance regimen. We used a single-center, nonrandomised, retrospective, sequential study design to evaluate the efficacy and safety of alemtuzumab (n = 50) or antithymocyte globulin (n = 38) induction in combination with a prednisone-free, tacrolimus/sirolimus-based immunosuppression protocol. Kaplan-Meier analyses of long-term patient and graft survivals and rejection rates were determined according to induction agent. Secondary endpoints included the quality of renal allograft function, incidence of infectious and malignant complications, and cost considerations. Overall long-term patient and graft survival rates did not significantly differ between patients treated with alemtuzumab and antithymocyte globulin. Rejection rates were also nearly equivalent at 1 and 2 years. Viral infectious complications were statistically significantly lower in the alemtuzumab group. The cost of alemtuzumab induction was lower than antithymocyte globulin. Alemtuzumab induction followed by steroid-free maintenance therapy with a tacrolimus/sirolimus-based immunosuppression regimen provided an effective, safe and cost-conscious approach to SPK transplantation.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Alemtuzumab; anti-thymocyte globulin; pancreas transplantation; steroid sparing

Document Type: Research Article

Affiliations: 1: Department of Surgery, Division of Transplantation 2: Department of Medicine, Division of Nephrology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA 3: Cardiovascular Magnetic Resonance Center, Duke University Medical Center, Durham, North Carolina, USA

Publication date: 01 February 2006

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more